Skip to content

Capital market commentary from Karin Kunrath, Chief Investment Officer of Raiffeisen KAG

This raises the question of whether the price levels on the (US) stock markets are justified when current negative factors appear to be largely ignored and investors are already focusing on the coming quarters or next year. It is true that companies have repeatedly been able to respond more quickly and effectively to challenging conditions in the past than could have been expected. This seems to justify a healthy degree of optimism and a willingness to overlook immediate dampening effects.

Although there are still a number of uncertainties surrounding the erratic tariff policy, which poses a downside risk to growth and an upside risk to inflation for the US, its impact on the capital market has steadily declined in recent weeks, partly as a result of resilient macroeconomic data. On the other hand, pressure on the Fed to cut interest rates again is mounting. Especially since, on the one hand, there has been no significant rise in inflation to date despite the import tariffs already introduced and, on the other hand, the latest labor market data has fallen short of expectations.

The significantly downwardly revised earnings expectations for the second quarter were clearly exceeded during the reporting season, and the outlook for future earnings growth also appears quite constructive from today's perspective. The ambitious valuation level and the recent technical overbought situation on the stock market indicate that a great deal of optimism has been priced into share prices in a short period of time, making a phase of increased volatility more likely.

However, as long as the regular reality checks in the quarterly reports continue to be so positive, especially for leading US growth companies, and thus show that the effects of tariffs are manageable for the economy, the market should remain well supported. We currently have a neutral position in equities.

Overview of asset classes

This content is only intended for institutional investors.

More